Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Grupo de investigación alemán ofrece ensayos in vitro para la detección de organotoxicidad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20161011001
Publicado:
24/10/2016
Caducidad:
24/10/2017
Resumen:
Un grupo de I+D alemán ofrece ensayos in vitro basados en células para las industrias química y farmacéutica e investigación básica. Los ensayos in vitro se utilizan para investigar la hepatotoxicidad, neurotoxicidad e inmunoparálisis de leucocitos. Todos los ensayos se realizan conforme a la norma DIN EN ISO/IEC 17025:2005-08 para garantizar la alta precisión de los resultados. El grupo de investigación busca un socio con el fin de participar en proyectos de investigación e innovación o establecer acuerdos de cooperación técnica o licencia.

Details

Tittle:
Resarch group offers in-vitro test systems for the detection of organotoxicity
Summary:
A research and development (R-Y-D) group from the Northeast of Germany offers cell based in-vitro test systems for pharmaceutical and chemical industry as well as basic research. In vitro-tests systems are established for investigation of hepatocity, neurotoxicity and leucocyte immunoparalysis. The research group is seeking for partner for joint research and innovation projects or technical cooperation. Furthermore licensing of technologies is possible.
Description:
A research and development (R-Y-D) group from the Northeastern part of Germany offers a wide range of analytical and diagnostic methods. Cell-based biosensors are used for early detection of organ failure and assessment of prognosis in critically ill patients: Liver, nervous system and immune system.

Organ failure is associated with a high mortality and can be caused by acute diseases or medication. Organ damage caused by medication is the most common reason for withdrawing drugs that have already been approved for the market.

However, there is no reliable test system available at present to detect organ failure at an early stage. This gave rise to the development of a microtiter plate assay based on human cells that can be used to detect organ failure at an early stage in a clinical setting and to evaluate the toxicity of drugs and medical devices. By optimizing and standardizing the procedure, reliable statements can be made with regard to exogenous and endogenous toxicity.

In-vitro test systems are implemented to replace, reduce and refine (3R principle) animal trails. The assays are useable for pharmaceutical (toxicology, drug development, efficacy testing, bioactivity assays, quality control) and chemical industry (toxicity testing) as well as basic research.

The following in-vitro test systems are established for investigation of hepatotoxicity, neurotoxicity and leukocyte immunoparalysis.

All tests are performed according to DIN EN ISO/IEC 17025:2005-08 to ensure a high accuracy of results.

The R-Y-D group looks for partners for joint research and innovation projects or technical cooperation. Licensing of technologies is also possible.

Partners could be companies that want to test (in-vitro) their products with regard to hepatotoxicity, neurotoxicity and leukocyt immunoparalysis. Also research institutions that want to cooperate within Horizon 2002 or other R-Y-D projects could become a partner. License agreements, research or technical cooperation agreements are possible.
Advantages and Innovations:
The cell-based test systems can be used to replace, reduce and refine (3R principle) animal trails. The assays are useable for pharmaceutical (toxicology, drug development, efficacy testing bioactivity assays, quality control) and chemical industry (toxicity testing) as well as basic research.
Stage of Development:
Already on the market
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
The preferred partnership is with companies that want to test (in-vitro) their products with regard to hepatotoxicity, neurotoxicity and leukocyte immunoparalysis.

Also a cooperation with research institutions within H2020 and other R-Y-D projects is possible.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06001019 Tecnologías de células madre